Lactobacillus johnsonii N6.2
Lactobacillus johnsonii N6.2 has a moderately developed clinical evidence base, anchored by multiple double-blind, randomized human trials evaluating safety, tolerability, and host immune responses in healthy adults. These trials have examined immune function and specific immune cell populations. In vitro research has examined the strain's extracellular vesicles, including activity in relation to murine norovirus, immunomodulatory phospholipid interactions with dendritic cells, and pancreatic cell signaling; these remain preliminary and unconfirmed in human trials. Animal model work has explored gut flora-related autoimmunity research in an early-stage context. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 20 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 5 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
25 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 28659913 →Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults· Frontiers in Immunology · 2017
-
[2]
Source →Immunological effects of Lactobacillus johnsonii N6.2 in healthy adults: A double‐blind, randomized trial· The FASEB Journal · 2017
-
[3]
Source →A Double‐Blind, Randomized Human Trial To Evaluate The Safety, Tolerability, And Host Response To Lactobacillus johnsonii N6.2· The FASEB Journal · 2016